Manufacturing Due Diligence: The 10 Questions Every Investor Should Ask

← Back to All Insights

Most VC and PE investors excel at evaluating clinical differentiation, reimbursement potential, and market size. But manufacturing—the unglamorous back-office function—remains the most systematically underestimated risk factor in medical device portfolios. Companies with pristine clinical data, FDA (Food and Drug Administration) clearance, and $50M in committed revenue have crumbled because they couldn't manufacture at scale. The costs are staggering: design transfers failing, COGS (cost of goods sold) exploding, quality systems buckling under commercial volumes.

This article breaks down the 10 critical manufacturing questions investors consistently miss, and explains how Vantage's proprietary framework specifically evaluates manufacturing readiness before problems become portfolio disasters.

Where the Margin Story Collapses

You already know manufacturing matters. What's less obvious is how quickly it becomes the binding constraint on your entire investment thesis. Under FDA 21 CFR Part 820 (Quality System Regulation), a quality system failure doesn't just mean recalls—it triggers warning letters, consent decrees, and permanent damage to market access. For a portfolio company, that's not an operational hiccup. It's a regulatory event that can wipe out valuations overnight.

Beyond compliance, manufacturing is often where the margin story collapses. A device may have a target gross margin of 75%—but that assumes COGS stays flat as volumes scale 100x. In reality, most medical device companies underestimate scaling costs by 30-50%, particularly when transitioning from prototype contract manufacturing to commercial-volume production.

The 10 Critical Manufacturing Questions

1. Single-Source Supplier Risk: How Many Critical Components Have Backup Plans?

This is the question that separates scalable manufacturers from science projects. Identify components that are single-sourced—meaning only one approved supplier under the device's quality agreement. For Class II and III devices, FDA expects redundancy for critical components. If a supplier ceases operations, you can't simply swap in a competitor's part without new validation, biocompatibility testing (if it contacts tissue), and potentially FDA notification. That's not a procurement problem—it's a production shutdown.

Red flag: A company with 12+ critical single-source components. Higher risk: those supplied by small, undercapitalized vendors. Supply chain disruptions have cost companies $5-15M in lost revenue and triggered class recalls. But the clinical dimension is equally important: if the single-sourced component is biocompatible material or a sensor that directly affects clinical performance, a supply disruption doesn't just delay revenue—it creates a patient safety gap that draws FDA scrutiny.

2. COGS Trajectory: What's the Actual Path to Target Gross Margin?

Companies always show you the "target" COGS at scale. What you need is the transition plan: COGS at 1,000 units/month, 5,000 units/month, and 20,000+ units/month. This reveals whether margin improvement depends on capturing new cost leverage or simply volume absorption. If a company's margin road map requires custom tooling, new suppliers, or design changes that haven't been validated yet, that's material risk.

3. Design Transfer Readiness: Is the Design Actually Manufacturable at Scale?

Prototype designs often assume manual assembly, hand-optimization, and tolerance stacks that fall apart at scale. ISO (International Organization for Standardization) 13485:2016 requires documented design transfer, manufacturing capability studies (process capability, Cpk—process capability index), and validation of production processes. The question: has this been done, or is it on the post-FDA-clearance roadmap?

If design transfer happens post-clearance, you're in an extremely risky window—the device is already marketed, but production hasn't been proven at commercial scale. Companies commonly discover manufacturability issues 3-4 months into commercial production, forcing emergency design changes or temporary volume constraints. What a manufacturing consultant sees here is a timeline risk. What a physician sees is a clinical risk: design changes at scale can introduce variance that affects device performance, biocompatibility, or procedural outcomes—issues that may not surface until post-market surveillance catches adverse events.

4. Quality System Maturity: Is the QMS ISO 13485-Compliant TODAY?

Many early-stage device companies operate under a "startup-grade" QMS (quality management system): informal change control, loose document management, minimal statistical process controls. Under FDA 21 CFR 820, a company may function, but they're one FDA warning letter away from production shutdown. More critically, investors and acquirers view QMS maturity as a proxy for execution discipline and regulatory stability.

Here's what "mature" looks like: ISO 13485 certification (or active third-party audit demonstrating compliance), documented change control procedures with impact assessments, real-time statistical process controls, supplier audits at least annually, and corrective action systems with documented effectiveness checks. The clinical angle investors miss: QMS maturity directly correlates with post-market complaint rates and adverse event frequency. A weak quality system doesn't just create regulatory exposure—it creates clinical exposure that erodes physician confidence and adoption velocity.

5. Contract Manufacturer Lock-In: Who Actually Controls Manufacturing?

Many early-stage companies outsource manufacturing to contract manufacturers (CMs)—often the right decision. But the structure matters enormously. Red flags:

• Proprietary designs/tooling owned by CM: The CM controls your critical IP (intellectual property). If you outgrow them or hit a price dispute, you're trapped.
• Single-CM dependence: If they have capacity constraints or go bankrupt, you lose production overnight.
• Vague quality agreements: The CM isn't contractually bound to maintain specific QMS standards or process controls.
• No audit rights: You can't verify they're actually following validated procedures.

Better structure: Shared IP ownership, dual-sourcing agreements with clearly defined handover procedures, quarterly audits, and documented SLAs (service level agreements) around quality metrics.

6. Scale-Up Risk: What Happens Between 100 and 10,000 Units per Month?

This is where most companies fail. Prototype-scale manufacturing (100 units/month) is qualitatively different from commercial scale (10,000 units/month). Risks include:

• Bottlenecks in manual assembly steps that weren't visible at small scale
• Quality variance when operators multiply from 2 to 20
• Supply chain volatility when single suppliers suddenly can't absorb 10x demand
• Facility constraints: space for inventory, staging, rework

Companies should have a documented scale-up plan with pilot runs at progressively larger volumes, process capability studies proving the design works at 1,000+ units/month, and contingency supply agreements.

7. FDA QSR Compliance Readiness: Is Your Quality System Audit-Ready?

FDA inspections under 21 CFR 820 focus on design controls, risk management, supplier management, change control, and corrective/preventive actions. If your company hasn't been through an FDA inspection, this is unknown risk. We recommend a pre-submission meeting with FDA after your design freeze (pre-clearance) that includes discussion of manufacturing locations and quality systems. This creates accountability and identifies gaps early.

8. Regulatory Classification Alignment: Does Your Manufacturing Setup Match Your Intended Market Classification?

If you're planning a 510(k) (premarket submission demonstrating substantial equivalence) but your device requires sterile processing, you may need Class II manufacturing controls. If you're planning a Class II but your manufacturing is overseas without US oversight, that's a red flag for FDA inspections. Misalignment between device classification and manufacturing capability can delay clearance or trigger additional compliance requirements post-approval.

9. Reimbursement-Linked Manufacturing Assumptions: Will Payers' Requirements Drive Manufacturing Costs?

Some reimbursement models require specific manufacturing or tracking capabilities. For example, if CMS (Centers for Medicare & Medicaid Services) requires unique device identification (UDI) beyond basic barcode compliance, that adds downstream cost. If your health economics model assumes a specific cost structure that only works with lower-cost overseas manufacturing, but supply chain disruptions force domestic shift, margins collapse.

10. Manufacturing Risk Allocation: Who Bears Scaling, Quality, and Regulatory Risk?

In investment documents, this is buried in legal terms, but it's critical: if manufacturing underperforms, who pays? If a contract manufacturer fails quality audits, does the CM remediate or does the company bear recall costs? If scale-up takes 6 months longer than projected, who funds operations? These allocations should be explicit in CM agreements and investment term sheets.

How Vantage Evaluates Manufacturing Readiness

Our CTO, Aswini Ravinutala, was part of the Axonics operations engineering team through Boston Scientific's $4.1B acquisition — working across design controls, manufacturing scale-up, and quality systems for Class II/III devices. That direct operational experience shapes how Vantage evaluates manufacturing risk. Within our proprietary due diligence framework, manufacturing readiness spans four distinct assessment areas:

1. Operations & Manufacturing (Category 7): Quality system maturity, regulatory alignment, supply chain redundancy, CM relationship structure
2. Regulatory & Compliance (Category 2): 21 CFR 820 readiness, design transfer validation, FDA pre-submission strategy
3. Financial Sustainability (Category 14): True COGS trajectory, gross margin realism, manufacturing capital requirements
4. Execution Capability (Category 16): Manufacturing team experience, track record scaling similar devices

We score each area, then synthesize into an overall manufacturing risk rating. Companies scoring "Yellow" (moderate risk) typically have one or two areas of concern—maybe immature QMS but a strong contract manufacturer, or single-source component risk but credible backup plans. Companies scoring "Red" have systemic manufacturing risk: inadequate quality systems, unvalidated scale-up plans, and unqualified manufacturing leadership.

The Bottom Line

Manufacturing risk is often invisible until it's catastrophic. By the time a company hits commercial scale, if quality systems haven't been built, supply chain redundancy isn't in place, and design-for-manufacturability isn't validated, the cost of remediation can consume years of runway. Investors who dig into these 10 questions—and demand substantive, detailed answers—separate the companies that scale smoothly from those that stall.

Vantage pairs physician-level clinical diligence with hands-on manufacturing engineering expertise—the combination that lets investors evaluate whether a device company can actually build what it's selling, at scale, profitably. The best time to assess manufacturing readiness is before you invest, not when your portfolio company is 6 months away from commercial launch and just discovering that their contract manufacturer can't hit volume targets.

"Manufacturing risk is the difference between a valuation and a value destruction event."

Concerned About Manufacturing Readiness?

Vantage's proprietary framework evaluates manufacturing readiness with both clinical and engineering rigor. If you have a portfolio company approaching scale or a target in active diligence, let's assess the risk.

Request a Confidential Assessment Download Red Flags Guide